Detection of bladder cancer with aberrantly fucosylated ITGA3

Tietueen suppeat tiedot
dc.contributor.authorIslam Md Khirul
dc.contributor.authorSyed Parvez
dc.contributor.authorDhondt Bert
dc.contributor.authorGidwani Kamlesh
dc.contributor.authorPettersson Kim
dc.contributor.authorLamminmäki Urpo
dc.contributor.authorLeivo Janne
dc.contributor.organizationfi=biotekniikka|en=Biotechnology|
dc.contributor.organizationfi=bioteknologian laitos|en=Department of Life Technologies|
dc.contributor.organization-code1.2.246.10.2458963.20.66532595361
dc.contributor.organization-code1.2.246.10.2458963.20.98373201676
dc.converis.publication-id66651036
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/66651036
dc.date.accessioned2022-10-27T11:49:11Z
dc.date.available2022-10-27T11:49:11Z
dc.description.abstract<p>We describe a simple, non-invasive assay to identify fucosylated-glycoisoform of integrin alpha-3 (ITGA3) directly from unprocessed urine. ITGA3 was detected directly from the urine of bladder cancer (BlCa) (n = 13) and benign prostatic hyperplasia (BPH) (n = 9) patients with the use of lectins coated on europium-dopednanoparticles (Eu<sup>3+</sup>-NPs). Lectin <em>Ulex europaeus agglutinin</em>-I (UEA) showed enhanced binding with BlCaderived ITGA3. The evaluation with individual samples showed that a glycovariant ITGA3-UEA assay could significantly discriminate BlCa from BPH patients (<em>p</em> = 0.007). The detection of aberrantly fucosylated-isoform of ITGA3 from urine can be used to distinguish BlCa from age-matched benign controls in a simple sandwich assay.</p>
dc.identifier.eissn1096-0309
dc.identifier.jour-issn0003-2697
dc.identifier.olddbid172071
dc.identifier.oldhandle10024/155165
dc.identifier.urihttps://www.utupub.fi/handle/11111/29739
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0003269721001846?via%3Dihub
dc.identifier.urnURN:NBN:fi-fe2021093047912
dc.language.isoen
dc.okm.affiliatedauthorIslam, Khirul
dc.okm.affiliatedauthorGidwani, Kamlesh
dc.okm.affiliatedauthorPettersson, Kim
dc.okm.affiliatedauthorLamminmäki, Urpo
dc.okm.affiliatedauthorLeivo, Janne
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline318 Medical biotechnologyen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.discipline318 Lääketieteen bioteknologiafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherAcademic Press Inc Elsevier Science
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.articlenumberARTN 114283
dc.relation.doi10.1016/j.ab.2021.114283
dc.relation.ispartofjournalAnalytical Biochemistry
dc.relation.volume628
dc.source.identifierhttps://www.utupub.fi/handle/10024/155165
dc.titleDetection of bladder cancer with aberrantly fucosylated ITGA3
dc.year.issued2021

Tiedostot

Näytetään 1 - 1 / 1
Name:
1-s2.0-S0003269721001846-main.pdf
Size:
1.42 MB
Format:
Adobe Portable Document Format
Description:
Publisher's PDF
Lataa

Kokoelmat

Rinnakkaistallenteet